Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Sep 30;39(4):201–206. [Article in Spanish] doi: 10.1157/13100844

PAPPS cardiovascular 2005: un análisis crítico

Félix Miguel García a,⁎, Alejandra García Ortiz b, M José Montero Alonso a, Alejandro Merino Senovilla c, Ruperto Sanz Cantalapiedra d, José Ángel Maderuelo Fernández e
PMCID: PMC7664551  PMID: 17428425

The content is available as a PDF (148.8 KB).

Bibliografía

  • 1.Villar-Álvarez F., Villar-Álvarez F., Maiques-Galán A., Brotons-Cuixart C., Torcal-Laguna J., Banegas-Banegas J.J. Recomendaciones preventivas cardiovasculares en atención primaria. PAPPS. Aten Primaria. 2005;36(Supl 2):11–26. [Google Scholar]
  • 2.De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610. doi: 10.1016/s0195-668x(03)00347-6. [DOI] [PubMed] [Google Scholar]
  • 3.Comité Español Interdisciplinario para la Prevención Cardiovascular. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Madrid: Ministerio de Sanidad y Consumo; 2004.
  • 4.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–2997. doi: 10.1001/jama.288.23.2981. [DOI] [PubMed] [Google Scholar]
  • 5.Psaty B.M., Lumley T., Furbey C.D., Schellenbaum G., Pahor M., Alderman M.H. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA. 2003;289:2534–2544. doi: 10.1001/jama.289.19.2534. [DOI] [PubMed] [Google Scholar]
  • 6.Dahlof B., Devereux R.B., Kjeldsen S.E. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. doi: 10.1016/S0140-6736(02)08089-3. [DOI] [PubMed] [Google Scholar]
  • 7.Wilhelmsen L., Berglund G., Elmfeldt D., Fitzsimons T., Holzgreve H., Hosie J. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPY trial. J Hypertens. 1987;5:561–572. doi: 10.1097/00004872-198710000-00009. [DOI] [PubMed] [Google Scholar]
  • 8.Neaton J.D., Grim R.H., Prineas R.J., Stamler J., Grandits G.A., Elmer P.J. Treatment of mild hypertension study. Final results. JAMA. 1993;270:713–724. [PubMed] [Google Scholar]
  • 9.Tatti P., Pahor M., Byington R.P., Di Mauro P., Guarisco R., Strollo G. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603. doi: 10.2337/diacare.21.4.597. [DOI] [PubMed] [Google Scholar]
  • 10.Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstatt S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compred with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652. doi: 10.1056/NEJM199803053381003. [DOI] [PubMed] [Google Scholar]
  • 11.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care. JAMA. 2002;288:2998–3007. doi: 10.1001/jama.288.23.2998. [DOI] [PubMed] [Google Scholar]
  • 12.Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158. doi: 10.1016/S0140-6736(03)12948-0. [DOI] [PubMed] [Google Scholar]
  • 13.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. [Google Scholar]
  • 14.Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997;20:614–620. doi: 10.2337/diacare.20.4.614. [DOI] [PubMed] [Google Scholar]
  • 15.Haffner S.M., Alexander C.M., Cook T.J., Boccuzzi S.J., Musliner T.A., Pedersen T.R. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661–2667. doi: 10.1001/archinte.159.22.2661. [DOI] [PubMed] [Google Scholar]
  • 16.Goldberg R.B., Mellies M.J., Sacks F.M., Moyé L.A., Howard B.V., Howard W.W.J. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation. 1998;98:2513–2519. doi: 10.1161/01.cir.98.23.2513. [DOI] [PubMed] [Google Scholar]
  • 17.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowernig with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016. [Google Scholar]
  • 18.Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J. Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med. 2002;162:2597–2604. doi: 10.1001/archinte.162.22.2597. [DOI] [PubMed] [Google Scholar]
  • 19.Colhoun H.M., Betteridge D.J., Durrington P.N., Timan G.A., Niel H.A., Livingstone S.J. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Studt (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–696. doi: 10.1016/S0140-6736(04)16895-5. [DOI] [PubMed] [Google Scholar]
  • 20.Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630. doi: 10.1016/s0140-6736(02)11600-x. [DOI] [PubMed] [Google Scholar]
  • 21.Downs G.R., Clearfield M., Weiss S., Whitney E., Shapiro D.R., Beere P.A. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  • 22.Koskinen P., Mänttäri M., Manninen V., Huttunen J.K., Heinonen O.P., Heikki Frick M. Coronay heart disease incidence in NIDDM patients In The Helsinki Heart Study. Diabetes Care. 1992;15:820–825. doi: 10.2337/diacare.15.7.820. [DOI] [PubMed] [Google Scholar]
  • 23.Hanefeld M., Fischer S., Schemechel H., Rothe G., Schultze J., Dude H. Diabetes intervention study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14:308–317. doi: 10.2337/diacare.14.4.308. [DOI] [PubMed] [Google Scholar]
  • 24.The SENDCAP Study Group Cardiovascular outcomes in type 2 diabetes. Diabetes Care. 1998;21:641–648. doi: 10.2337/diacare.21.4.641. [DOI] [PubMed] [Google Scholar]
  • 25.LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435. doi: 10.1056/NEJMoa050461. [DOI] [PubMed] [Google Scholar]
  • 26.Masana L., Plana N. Planificación orientada por objetivos en el tratamiento de la hipercolesterolemia. Med Clin (Barc) 2005;124:108–110. doi: 10.1157/13070853. [DOI] [PubMed] [Google Scholar]
  • 27.Pignone M., Phillips C., Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000;321:983–986. doi: 10.1136/bmj.321.7267.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Do statins have a role in primary prevention? Therapeutics Letter 2003. Disponible en : www.ti.ubc.ca.
  • 29.Jackson P.R., Wallis E.J., Haq I.U., Ramsay E. Statins for primary prevention: at what coronary risk is safety assured? J Clin Pharmacol. 2001;52:439–446. doi: 10.1046/j.0306-5251.2001.01478.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Cucherat M., Lievre M., Gueyffier F. Clinical benefits of cholesterol lowering treatments. Meta-analysis of randomized therapeutic trials. Presse Med. 2000;29:965–976. [PubMed] [Google Scholar]
  • 31.Vrecer M., Turk S., Drinovec J., Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomiced trials. Int J Clin Pharmacol Ther. 2003;41:567–577. doi: 10.5414/cpp41567. [DOI] [PubMed] [Google Scholar]
  • 32.Committee of Principal Investigation A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40:1069–1118. doi: 10.1136/hrt.40.10.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Grundy S.M., Cleeman J.I., Bairey Merz C.N., Brewer H.B., Jr, Clark L.T., Hunninghake D.B., for the Coordinating Committee of the National Cholesterol Education Program Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239. doi: 10.1161/01.CIR.0000133317.49796.0E. [DOI] [PubMed] [Google Scholar]
  • 34.Marrugat J., D’Agostino R., Sullivan L., Elosua R., Wilson P., Ordovás J. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253–261. doi: 10.1016/s0300-8932(03)76861-4. [DOI] [PubMed] [Google Scholar]
  • 35.Marrugat J., Comin J., Elosua R., Ramos R., Solanas P., Nam B.H. Validity of an adaptation of the Framingham cardiovascular risk function: the verifica study. Eur Heart J [Serial in the Internet] 2005 doi: 10.1136/jech.2005.038505. (accedido 14 Feb 2006). Disponible en: http://www.escardio.org/knowledge/congresses/abol/presentation?id=23668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Marrugat J., Subirana I., Comín E., Cabezas C., Vila J., Elosua R., For the VERIFICA Investigators Validity of an adaptation of the framingham cardiovascular risk function: the verifica study. J Epidemiol Comm Health. 2007;61:40–47. doi: 10.1136/jech.2005.038505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ramos R., Marrugat J. Valoración del riesgo cardiovascular en la población española. In: Del Río Ligori A., editor. Manual de cardiología preventiva. SMC; Madrid: 2005. [Google Scholar]
  • 38.Mostaza J.M., Vicente F., Taboada M., Laguna F., Echaniz A., García-Iglesias F. La aplicación de las tablas del SCORE a varones de edad avanzada triplica el número de sujetos clasificados de alto riesgo en comparación con la función de Framingham. Med Clin (Barc) 2005;124:487–490. doi: 10.1157/13073561. [DOI] [PubMed] [Google Scholar]
  • 39.González C., Rodilla E., Costa J.A., Justicia J., Pascual J.M. Comparación entre el algoritmo de Framingham y el de SCORE en el cálculo del riesgo cardiovascular en sujetos de 40-65 años. Med Clin (Barc) 2006;126:527–531. doi: 10.1157/13087144. [DOI] [PubMed] [Google Scholar]
  • 40.Maiques A., Antón F., Franch M., Albert X., Aleixandre E., Collado A. Riesgo cardiovascular del SCORE comparado con el de Framingham. Consecuencias del cambio propuesto por las sociedades europeas. Med Clin (Barc) 2004;123:681–685. doi: 10.1016/s0025-7753(04)75330-0. [DOI] [PubMed] [Google Scholar]
  • 41.García L, Gómez MA, Sánchez A, Rodríguez MJ, González LJ, Miranda AI, et al. Cardiovascular risk evaluation in hypertensive patients with framingham and score scales. Comunicación presentada al Congreso Europeo de Hipertensión. Paris 2004. Disponible en: http://www.laalamedilla.org/Investigacion/comunicaciones2004.htm
  • 42.Marrugat J., D’Agostino R., Sullivan L., Elosúa R., Wilson P., Ordovas J. An adaptation of the Framingham coronary Heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57:634–638. doi: 10.1136/jech.57.8.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Miguel F., García A., Montero M.J. Prevención primaria con estatinas, consensos y tablas de riesgo. Aten Primaria. 2005;36:31–38. doi: 10.1157/13075929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J. European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardio Prev Rev. 2003;10(Suppl 1):S1–S78. doi: 10.1016/s0195-668x(03)00347-6. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES